Abstract: A technique for implementing an clock tree distribution network having a clock buffer and a plurality of LC tanks that each take into \consideration local capacitance distributions and conductor resistances. An AC-based sizing formulation is applied to the buffer and to the LC tanks so as to reduce the total buffer area. The technique is iterative and can be fully automated while also reducing clock distribution power consumption.

Abstract: A method of implementing a VLSI clock network is implemented. That method includes a step of generating an initial VLSI clock grid for incorporation on a silicon die. An input grid buffer is then sized and implemented for the VLSI clock grid. LC tanks are then placed and sized in the VLSI clock grid to implement a resonant tank clock grid and the input grid buffer is resized. A check of the resonant tank design criteria is then made. If the design criteria are met the resonant VLSI clock grid with its LC tanks is implemented. If not, another attempt at implementing a suitable LC tanks placement and sizing is made. The process iterates until a VLSI clock grid that meets the design criteria is obtained.

Abstract: A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-?-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis.

Abstract: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.

Abstract: The present invention provides metal-free abnormal N-heterocyclic carbenes, also known as imidazol-5-ylidenes and metal complexes of abnormal N-heterocyclic carbenes. The present invention also provides methods of making metal-free abnormal N-heterocyclic carbenes and metal complexes of abnormal N-heterocyclic carbenes. The present invention also provides methods of using metal-free abnormal N-heterocyclic carbenes and metal complexes of abnormal N-heterocyclic carbenes in catalytic reactions.

Abstract: The invention provides modified Transferrin (Tf) molecules and conjugates of the Tf molecules with a therapeutic agent. The invention also provides methods of treating cancer wherein the therapeutic agents are chemotherapeutic agents. The modified Tf molecules improve the delivery of the conjugated agent to a target tissue. In some embodiments, the modified Tf molecule has a mutation which decreases the release of bound iron from a Tf complex. The complex can also contain, for instance, a carbonate, oxalate, or other anion to stabilize the Tf iron complex.

Abstract: Pharmaceutical compositions having at least one crystal protein and a nicotinic acetylcholine receptor agonist in amounts effective to inhibit a parasitic worm or helminth infection in a vertebrate or mammal are described. Methods for treating a parasitic worm or helminth infection in a subject are also described. The methods include administering to the subject a therapeutically effective amount of the at least one crystal protein and a nicotinic acetylcholine receptor agonist. The crystal proteins can be isolated from Bacillus thuringiensis and include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A. The nicotinic acetylcholine receptor agonist can be from the levamisole family, which include levamisole, pyrantel, and tribendimidine.

Abstract: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the treatment of a central nervous system disease or disorder or for the prevention or reduction of ischemia-reperfusion injury using the amiloride conjugates of the present invention.

Abstract: The present invention relates to retroviral vectors, particularly lentiviral vectors, pseudotyped with Sindbis envelope and targeted to specific cell types via a targeting moiety linked to the envelope.

Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

Abstract: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.

Abstract: Methods of microscopic imaging of biological tissue using adaptive optics technology to improve the image focus and sharpness. Wavefront measurements are taken by using a novel method of seeding biological tissue by using a fluorescent microsphere as a “guide star” as a natural point-source reference. The current methods are capable of improving the Strehl ratio of modern biological microscopes as much as 15 times.

Abstract: The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.

Abstract: A method for preparing highly dense functional oxides with crystallite size in the range of 10-20 nm. Using a high pressure modification of a the Spark Plasma Sintering (SPS) technique, rapid thermal cycles (<10 min) coupled with very rapid pressure increase up to 1 GPa can be obtained allowing high degree of compaction and very limited grain growth. This combination of techniques was employed to produce the finest-grained ceramics ever prepared in bulk form in the case of fully stabilized zirconia and Sm-doped Ceria.

Abstract: A method for opening a portion of a passageway of a patient is disclosed. The patient has a first metallic structure attached to a portion of the patient's neck. The method includes obtaining a second magnetic structure, placing the second magnetic structure proximate the first metallic structure attached to the portion of the patient's neck, and pulling the second magnetic structure away from the patient's neck to thereby open the passageway.

Abstract: The present invention provides nucleic acids encoding porcine taste receptors, polypeptides encoded by the nucleic acids, and methods of using the nucleic acids and polypeptides to identify compounds that enhance umami taste.

Abstract: Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers/tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.

Abstract: The invention provides methods for alleviating eye disorders due to increased intraocular pressure (“IOP”) or inflammation by administering to the eye or eyes of an individual in need thereof a cis-epoxyeicosatrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. The invention further provides for reducing IOP or inflammation by methods in which the sEH inhibitor or EETs, or both, are administered systemically. In some embodiments, the methods comprise administering to the individual a nucleic acid encoding an inhibitor of sEH.

Abstract: The present invention provides methods of treating avian pulmonary hypertension syndrome by administering to an avian subject a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase (“sEHI”), alone or co-administered in combination with a cis-epoxyeicosantrienoic acid (“EET”). The invention also provides nucleic acid and amino acid sequences of an avian soluble epoxide hydrolase.

Abstract: The present invention provides genomic markers for determining the presence or absence of breast cancer. The invention further demonstrates that inhibition of MEN1 reduces breast or prostate cancer proliferation, thereby demonstrating that inhibition of MEN1 activity or expression can be used to reduce breast cancer or prostate cancer proliferation in an individual in need thereof.